Research in contextEvidence before this studyAutism spectrum disorder is heterogenic developmental problem with strong and complicated genetic bases. Several shared genes have been found between schizophrenia and Autism. Based on pub-med, science direct and Scopus data bases genetic variants and gene expression alterations of Neureguline1 (*NRG1*) had been reported in schizophrenic patients. Several studies also reported single nucleotide polymorphisms in *NRG1* associated with autism. We started working on Neureguline1 (*NRG1*) in psychiatric disorder in 2013 by a case control study in gene expression of *NRG1* types in schizophrenic patients and possible correlation with clinical symptoms. Then we continued the same approach in bipolar disorder, attention deficit hyperactivity disorder and Autism until now.Added value of this studyFindings of present study help to clarify the role of *NRG1* in etiology of Autism and also its role in executive functions not just in autistic children also in normal children as well. In the other hand our study brings new evidence about disruption in excitation/inhibition (E/I) balance in autism. In addition sex effect and correlation of each types of NRG1 with severity of symptoms in patients showed more detail about pathophisiology of autism.Implications of all the available evidencePresent study may help to understand about the role of epidermal growth factors such as *NRG1* in etiology of autism. Also study of each types of *NRG1* could clarify the role of each molecular pathway in neurons and neuroglia in severity of autism symptoms and executive functions deficits. Future studies may consider the expression of *NRG1* expression in neuron made by induced pluripotent stem cells from children with autism. Also future study may consider drug therapy to increase the expression of *NRG1* that based on our findings may reduce the severity of autism symptoms and also improve the executive functions ability in children.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Autism spectrum disorder (ASD) is a complex psychiatric disorder which characterized by social and communication deficits, language impairment and ritualistic or repetitive behaviors and can be diagnosed after age three \[[@bb0005]\]. ASD has different prevalence in different countries. Center for disease control and prevention (CDC) of United States has estimates 1 in 59 children have been identified with ASD in USA. Studies in Asia, Europe, and North America have identified 1% average prevalence of ASD \[[@bb0010]\]. Etiology of autism spectrum is not clear but high heritability and strong genetic bases of disorder including chromosomal abnormalities and point mutations were reported in number of studies. Genetic bases of ASD have elaborated due to interactions among multiple genes and epigenetic factors which influence gene expression \[[@bb0015]\].

Number of shared genes were identified which are involved in etiology of psychiatric disorders such as Schizophrenia(SCZ), bipolar disorder, attention deficit hyperactivity disorder(ADHD), major depressive disorder(MDD) and ASD \[[@bb0020]\].Previous gene expression studies in autism spectrum disorder had been revealed expression changes in several genes in different pathways. Expression alteration of genes that are involved in serotonin pathway like *5-HTT* \[[@bb0025]\], development and functions of nervous system like *CNTNAP2* and transcription factors such as *FOXP1* and *FOXP2* were reported in ASD patients \[[@bb0030]\].

Neuregulin1 (*NRG1*) gene, located in 8p12, plays critical role in development of central nervous system and activation of neurotransmitter receptors, including glutamate receptors \[[@bb0035]\]. Several genes in human chromosome 8 are candidate genes in neuropsychiatric disorders. *VMAT1/SLC18A1*, *NRG1*, *PPP3CC* and *DPYSL2* in 8p12--13 are clearly associated with Schizophrenia and probably bipolar disorder \[[@bb0040]\].

The *NRG1* gene has at least 31 isoforms in mammal, which can be grouped into six types of proteins with different structures and distinct functional characteristics. *NRG1* types are involved in modulation of neuronal migration, synaptogenesis, glycogenesis, dendritic growth, neuron-glia communication, myelination and neurotransmission. Types I, II and III of *NRG1* express in human peripheral blood and types IV and V are brain specific \[[@bb0045]\]. Type I is related to acetylcholine receptor inducing activity, type II is a Glial growth factor and type III is a sensory and motor neuron-derived factor \[[@bb0050]\], so expression changes in each type could affect specific function in brain independently or with other types. Expression of each *NRG1* isoforms is distinctly regulated by neuronal activity \[[@bb0055]\].

Several polymorphisms and rare mutations in *NRG1* were found associated with schizophrenia \[[@bb0060]\]. Over expression of type I \[[@bb0065]\]and down expression of type III in hippocampus of schizophrenic patients were reported in post mortem studies \[[@bb0070]\].Zhang et al. were showed low expression of *NRG1* in peripheral blood of schizophrenia and Shibuya et al. later were detected decrease in serum level of *NRG1* in patients with chronic schizophrenia \[[@bb0075]\]. Studies on transgenic animal models have been showed over expression of *NRG1* type I could affect hippocampal functions and circuitry, mediated via inhibitory interneuron which induces impairment in hippocampus-dependent spatial working memory \[[@bb0080]\].Several shared genetic variants were found between schizophrenia and autism spectrum disorders especially in genes involved in synaptic activity \[[@bb0085]\].

Previous study about NRG1 expression in ASD mouse model showed positive correlation between *NRG1* mRNA level in microglia and peripheral blood mononuclear cells (PBMCs) in mice. It may support *NRG1* as potential peripheral marker. In the other hand mRNA levels of *NRG1* type III in PBMCs were positively correlated with impairments in social interaction in children with ASD which might strength evidences about *NRG1* role in etiology of Autism as well as other psychiatric disorders \[[@bb0090]\]. Recent studies bring evidence about down expression of *NRG1* types I, II and III in peripheral blood of methamphetamine and heroin dependent individuals as well as schizophrenic patients which are correlated with severity of psychotic symptoms in these patients \[[@bb0095]\].

Present study aimed to examine the expression level of types I, II and III of *NRG1* gene in peripheral blood of ASD patients. Several executive functions (EF) were examined in ASD and non psychiatric children. Also correlation of *NRG1* mRNA level with executive functions abilities were assessed.

2. Material and methods {#s0025}
=======================

 {#s0030}

### 2.1.1. Subject selection {#s0035}

The study was included 1540 unrelated ASD patients (1020 male,520 female)aged 7 to 11 years diagnosed by two independent senior psychiatrists by unstructured or semi structured behavioral observations in patients and interviews with patients, their parents and teachers based on DSM-V criteria and have been confirmed by exceeding threshold of Autism Diagnostic Observation Schedule (ADOS) score \[[@bb0010]\].Higher score in ADOS is referring to high sever symptoms in ASD patients. Control group was included 1490 unrelated control children (970 male, 520 female) aged 7 to11 years. Patients with IQ score (Wechsler Abbreviated Intelligence Scale, 1999) lower than 70 were excluded from study. All of the ASD samples were early diagnosed and did not start treatment when participated in study. Patients have been recruited from the outpatient psychiatric clinics of 18 provinces (from 31 provinces) of Iran. The subjects of control group were recruited from children who received regular medical checkups for school enrolment in local medical centers. The control children were recruited with matched sex, age, race, socioeconomic situation and familial situation to patients group and had no history of any psychological or somatic problem. Supplementary Table 1 showed matching statistical data. Statistical data of 24 patients with combined ASD and ADHD were excluded from study and finally 1540 patients included to the study. None of subjects or their parents had current or history of sever medical condition, neurological disorder, history of head trauma with loss of consciousness, any psycho-stimulant or opioid drug abuse and alcohol or nicotine dependence. All subjects\' parents were given an explanation on the purpose of the study and next, written informed consent has been provided. Study was approved by central ethical committee of Islamic Azad University.

### 2.1.2. Neuropsychological tests {#s0040}

Four neuropsychological tests (as listed below) were performed to analyze response inhibition, vigilance and working memory as main executive functions (EF) which their deficiency had reported in ASD patients.

#### 2.1.2.1. 1) Integrated visual and auditory (IVA) continuous performance test (CPT) {#s0045}

The integrated visual and auditory (IVA) continuous performance test (CPT) was designed as screening and symptoms severity test of ADHD, but also using for several neurodevelopmental psychiatric disorders including ASD. The IVA associates vigilance and impulsivity in a balanced design by visual and auditory modalities. The visual response control quotient (VRCQ) and auditory response control quotient (ARCQ) are the primary dependent variables \[[@bb0100],[@bb0105]\].

#### 2.1.2.2. 2) IVA visual attention quotient (VAQ) and Auditory attention quotient (AAQ): {#s0050}

We used VAQ and AAQ as primary dependent variables in this measure to examine the vigilance. Tests were performed based on previous studies method \[[@bb0105],[@bb0110]\]. The VRCQ, ARCQ, VAQ and AAQ are all part of IVA-CPT test.

#### 2.1.2.3. 3) Spatial span (SSP) of CANTABexpedio {#s0055}

Cambridge neuropsychological test automated battery (CANTABexpedio) examine cognitive domains including attention, executive function, memory, processing speed, and visuo-spatial ability. Spatial Span (SSP) measures both forward and reverse spatial memory span. Test was performed based on previous studies method \[[@bb0105],[@bb0110]\].

### 2.1.3. 4) Spatial working memory (SWM) {#s0060}

Spatial Working Memory (SWM) measures the ability to maintain spatial information and to subsequently manipulate the presented items in working memory. This test uses boxes and colors and is suitable for children. Method of performing test had followed based on previous researches \[[@bb0110]\]. The total spatial working memory between search errors (SWM Btwn Error) and strategy scores (SWM Strategy) were considered in results \[[@bb0110]\].

### 2.1.4. Blood sampling and quantitative real time PCR {#s0065}

Blood (5 ml) was collected from the cubital vein without tourniquet between 10.00 and 11.00 AM. Total RNA was extracted from peripheral blood samples immediately after samplings according to standard protocols using by RNA Purification kit (GeneJET™ RNA Purification Kit\#K0732, Thermo scientific - Fermentas, Latvia). Total RNA was treated with DNase for the removal of contaminating genomic DNA using DNase Treatment & Removal Reagents (DNase I, RNase-free (\#EN0521) Fermentas, Latvia), according to the manufacturers protocol. Quality of RNA was evaluated by Agarose gel electrophoresis and UV- spectroscopy. The cDNA was synthesized using a Transcription First Strand cDNA Synthesis Kit (RevertAid Premium First Strand cDNA Synthesis Kit \#K1652, Thermo scientific -Fermentas, Latvia) according to manufacturer\'s protocol. After alignment the sequence of all three types of *NRG1* gene and finding types\' specific sequences, primers designed by \"oligo7\" software and were blasted on NCBI website. The phosphoglycerate kinase 1 (PGK1) gene was used for normalization as an endogenous reference gene. Primers were provided in [Table 1](#t0005){ref-type="table"}. Agarose gel electrophoresis was used to verify the predicted size of PCR amplicons of genes. Standard curves for each gene were prepared using serial dilutions (1: 4) of pooled cDNA from total RNA extracted from blood samples of 10 control subjects. In each experiment, the R^2^ value of the standard curve was \>0.99 and no-template control assays was resulted in no detectable signal. Quantitative RT-PCR was performed by using SYBR green (Thermo Scientific Maxima SYBR Green/ROX qPCR Master Mix (2×) \#K0221, Thermo scientific - Fermentas, Latvia). CFX96 Touch Real-Time PCR Detection System (BIO-RAD, [California, United States](https://www.google.com/search?q=hercules+ca&stick=H4sIAAAAAAAAAOPgE-LSz9U3MC4wzDVPUeIAsQsrCwu1tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcUALCJywkQAAAA&sa=X&ved=0ahUKEwjoz5qM5P_JAhVM3SwKHfWYDSkQmxMIfigBMBI){#ir0005}) used for triplicate method Quantitative Real Time-PCR. Pfafle formula used to calculate the ratio. Quantitative Real time PCR and analysis of expression data were conducted based on previous study \[[@bb0115]\].Table 1Sequences of primers used for quantitative Real time PCR.Table 1Genes primerprimer sequence*PGK1*forward primer5'GTGCCAAATGGAACACGGAG3'*PGK1*reverse primer5'TGCCAAGTGGAGATGCAGAA3'*NRG1* type I forward primer5'AGCCTCAACTGAAGGAGCAT3'*NRG1* type I reverse primer5'ACTCCCCTCCATTCACACAG3'*NRG1* type II forward primer5'CCCTATCTGGTGAAGGTGCA3'*NRG1* type II reverse primer5'GTCGGGCTCCATGAAGAAGA3'*NRG1* type III forward primer5'ATCTGCATTGTCCCCATCCT3'*NRG1* type III reverse primer5'GCAGTTGCGTCCAGAGAAAT3'

2.2. Statistical analysis {#s0070}
-------------------------

Descriptive data are expressed as mean ± SD (range) and level of statistical significance was set at *P* \< 0.05.Compliance with normal distribution for continuous variables was assessed via the Kolmogorov-Smirnov test. Statistical differences were calculated by one-way ANOVA followed by independent Student\'s *t*-test for multiple group comparisons. Pearson correlation analysis was conducted to determine the relationship between variables. Bonferroni correction was used for [multiple comparisons](https://en.wikipedia.org/wiki/Multiple_comparisons){#ir0010} corrections. Statistical analysis was conducted by using SPSS version23.

3. Results {#s0075}
==========

Demographic and clinical data have been presented in [Table 2](#t0010){ref-type="table"}.Table 2Demographic and clinical variables (Means and Standard Deviations).Table 2VARIABLEASDNormalGender1020 male,520 female970 male, 520 femaleAge9.2 ± 1.69.4 ± 2.3Age of onset3.4 ± 1.2--illness time5.3 ± 3.4--IQ score91.32 ± 23.42102.4 ± 14.48VRCQ57.21 ± 37.6696.22 ± 17.28ARCQ66.29 ± 14.6297.46 ± 24.36VAQ59.31 ± 17.795.29 ± 28.15AAQ66.56 ± 28.1697.83 ± 20.49SSP3.32 ± 1.345.74 ± 0.89SWM Btwn Errors66.32 ± 16.1142.39 ± 26.48SWM Strategy40.21 ± 1.1531.38 ± 3.56[^1]

 {#s0080}

### 3.1.1. Gene expression results {#s0085}

Significant down regulation of all three types of *NRG1* in patient\'s group in compare with control subjects were detected. No significant correlation was found between gene expression results and age, age of onset, duration of illness and intelligence quality score. Exact *p* values and ratio for each type have been presented in [Table 3](#t0015){ref-type="table"}.Table 3Gene expression ratio (fold change) and *p* value for *NRG1* types between groups.Table 3GeneASD vs. Normal*NRG1* type IRatio: 0.63\
p value: 0.001*NRG1* type IIRatio: 0.65\
p value: 0.002*NRG1* type IIIRatio: 0.47\
p value: 0.001

### 3.1.2. Neuropsychological results and correlations with gene expression {#s0090}

#### 3.1.2.1. 1) IVA tests\' results {#s0095}

Significant deficiency and lower performance in ASD group in compare with control group were showed in both VRCQ (*P* value = 0.0002) and ARCQ (P value = 0.001). Also significant lower performances were detected in ASD group in compare with control group in VAQ (*P* value = 0.001) and AAQ (P value = 0.0001). In ASD group, correlation analysis between *NRG1* types expression with IVA tests results have showed significant correlation between down expression of type I and type III with lower performance of all IVA tests (VRCQ, ARCQ, VAQ and AAQ). Also down expression in type II were significantly correlated with lower performance of VRCQ. Analysis of correlation between *NRG1* expression level and IVA tests in all subjects as combined group showed significant correlation between down expression of type III with lower performance of all IVA tests. Results presented in [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}.Table 4Correlation of gene expression results with demographic and clinical characteristics in ASD patients.Table 4Gene expressionGenderAgeAge of onsetillness timeIQ scoreVRCQARCQVAQAAQSSPSWM Btwn ErrorsSWM Strategy*NRG1* type I*p* value:\
0.16\
r: - 0.14p value:\
0.36\
r: 0.07p value:\
0.25\
r: 0.03p value:\
0.13\
r: 0.08p value:\
0.19\
r: 0.04p value:\
0.001\
r: 0.83p value:\
0.001\
r: 0.86p value:\
0.001\
r: 0.78p value:\
0.002\
r: 0.72p value:\
0.0001\
r: 0.8p value:\
0.001\
r: −0.73p value:\
0.007\
r: - 0.63*NRG1* type IIp value:\
0.08\
r: 0.18p value:\
0.17\
r: - 0.12p value:\
0.12\
r: 0.1p value:\
0.17\
r: 0.07p value:\
0.15\
r: 0.05p value:\
0.001\
r: 0.72p value:\
0.08\
r: 0.37p value:\
0.16\
r: 0.29p value:\
0.46\
r: 0. 14p value:\
0.003\
r: 0.64p value:\
0.17\
r: - 0.26p value:\
0.34\
r: - 0.18*NRG1* type IIIp value:\
0.3\
r: 0.11p value:\
0.19\
r: 0.08p value:\
0.09\
r: 0.11p value:\
0.23\
r: 0.14p value:\
0.09\
r: 0.18p value:\
0.003\
r: 0.92p value:\
0.001\
r: 0.94p value:\
0.002\
r: 0.88p value:\
0.003\
r: 0.81p value:\
0.002\
r: 0.84p value:\
0.002\
r: - 0.89p value:\
0.001\
r: - 0.77[^2]Table 5Correlation of gene expression results with demographic and clinical characteristics in all subjects.Table 5Gene expressionGenderAgeIQ scoreVRCQARCQVAQAAQSSPSWM Btwn ErrorsSWM Strategy*NRG1* type Ip value:\
0.12\
r: - 0.9p value:\
0.16\
r: 0.09p value:\
0.23\
r: 0.11p value:\
0.17\
r: 0.15p value:\
0.44\
r: 0.18p value:\
0.11\
r: 0.23p value:\
0.14\
r: 0.19p value:\
0.37\
r: 0.04p value:\
0. 2\
r: −0.17p value:\
0.23\
r: −0.06*NRG1* type IIp value:\
0.07\
r: 0.11p value:\
0.9\
r: 0.03p value:\
0.07\
r: 0.16p value:\
0.14\
r:0.27p value:\
0.07\
r: 0.2p value:\
0.09\
r: 0.34p value:\
0.08\
r: 0.32p value:\
0.12\
r: 0.29p value:\
0.07\
r: - 0.3p value:\
0.14\
r: −0.12*NRG1* type IIIp value:\
0.4\
r: 0.13p value:\
0.1\
r: 0.2p value:\
0.13\
r: 0.2p value:\
0.002\
r:0.62p value:\
0.001\
r: 0.68p value:\
0.002\
r: 0.73p value:\
0.003\
r: 0.56p value:\
0.01\
r: 0.27p value:\
0.03\
r: - 0.41p value:\
0.002\
r: −0.53[^3]

### 3.1.3. 2) Working memory tests results {#s0100}

Difference of SSP (P value = 0.002), SWM Btwn Errors (P value = 0.001) and SWM strategy (P value = 0.001) were significant between ASD and control groups which indicate significant deficiency in working memory of ASD in compare with controls. Significant correlation was found between types of *NRG1* expression and working memory deficiency. In ASD group, significant correlations were detected between down expression of type I and III with increase of SWM Btwn Errors and SWM strategy score. Also significant correlations were detected between down expression of type I, type II and type III with decrease of SSP score. Correlations between *NRG1* expression level and working memory tests in all subjects as combined group showed significant correlation between down expression of type III with increase of SWM strategy score. Summary of all correlations have been provided in [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}.

### 3.1.4. Severity of symptoms in ASD and gene expression {#s0105}

Diagnosis of ASD patients, have been confirmed by ADOS tests. Also severity of symptoms and their relation with gene expression and executive functions patterns were assessed. As the patients were high function, age compatible module three had been used for all ASD patients. Findings revealed significant correlation between down expression of type II and higher score of ADOS (r: −0.66, *P* value = 0.003). In addition significant correlation was found between lower score of VRCQ and higher score of ADOS (r: −0.72, P value = 0.001).

### 3.1.5. Sex effect analysis in ASD group {#s0110}

Effects of gender in severity of symptoms, executive functions and *NRG1* expression had been assessed with in ASD group. Findings showed significant down expression of type III in boys in compare with girls (P value = 0.002). In the other hand significant increase of SWM strategy score (P value = 0.002) were found in males in compare with females. Also type III down expression was significantly correlated with increase of SWM strategy score in overall ASD group (P value = 0.001, *r* = −0.77) and in ASD girls (P value = 0.003, *r* = −0.62) and ASD boys (P value = 0.003, *r* = −0.71) as independent groups.

4. Discussion {#s0115}
=============

*NRG1* has been implicated as a susceptibility gene in schizophrenia and there are evidences that the pattern of expression of *NRG1* isoforms may alter in schizophrenia. Present study is one of the first studies of *NRG1* role in ASD patients and suggests *NRG1* as novel potential candidate gene in etiology of ASD. Unlike the previous post-mortem genome wide expression profiling study that showed slight down expression of *NRG1* in cortex tissue, strong down regulation of *NRG1* detected in present cohort study \[[@bb0120]\]. Neuropsychological results and correlations suggest potential *NRG1* role in executive functions specially response inhibition, vigilance and working memory which their deficits previously were reported in ASD patients. However these finding probably has been improved knowledge about *NRG1* role in neuropsychiatric disorder.

*NRG1* type I has a major role in neuronal plasticity which shows activity-dependent regulation, and involvement in neurotransmitter receptor expression regulations. Number of deregulations in neuronal activity such as seizures and long-term potentiation, affect type I expression. *NRG1* promotes the switch from the immature form of NMDAR, which contains primarily NR2B subunits to one containing more NR2C subunits in the central nervous system. *NRG1* also potentiates α7 nicotinic acetylcholine receptor transmission in hippocampal neurons, and expression of the β2 subunit of the γ-amino butyric acid receptor in cerebellar granule cells. Thus, significant decrease in type I expression in ASD patients may alter neuronal signaling of NRG1 per se, or induces abnormalities in maturation of NMDA receptors and GABA receptor signaling or may be both of them eventually in brain of ASD patients \[[@bb0125]\].

*NRG1* type II (GGF) expression is essential for development of cortical neurons, and promotes the transformation and differentiation of radial glial cells. Glial cells in turn are involved in cortical neuronal cell migration and differentiation. It may make it reasonable that down regulation of type II mRNA level could lead to putative abnormalities of oligodendroglial functions including those functions which is related to communication and abilities in ASD patients \[[@bb0125]\]. Also correlation between type II and ADOS score may relate to the role of low functioning of glial cells in severity of symptoms and cognitive disabilities in ASD patients.

*NRG1* type III (SMDF) is involved with early development and survival of the Schwann cells. Previous studies were confirmed the role of type III signaling in the maintenance of corticostriatal components and in the neural circuits involved in sensorimotor gating and working memory \[[@bb0130]\]. Nicodemus et al. were reported down expression of type III in hippocampus -which is the main region of memory in schizophrenic patients \[[@bb0070]\]. Down regulation of type III mRNA level in ASD patients could explains sensorimotor abnormalities such as language impairments (as sensorimotor related symptom) in these patients \[[@bb0135],[@bb0140]\].

*NRG1*-*ErbB4* signaling regulates the function of amygdale. Inhibition of NRG1-ErbB4 signaling which is natural consequence of *NRG1* down regulation, decrease GABAergic activity and disrupts the excitation/inhibition (E/I) balance. Altered E/I balance is a pathophysiological mechanism of many psychological diseases, such as autism and schizophrenia \[[@bb0145]\]. Different lines of evidence were showed reduced GABAergic signaling in the brains of autistics children. It may be related to down regulation of *NRG1* as an upper hand growth factor which is involved in signal transduction of GABAergic neurons. Significant down expression of type III in boys in compare with girls may strength the evidence about association of GABAergic signaling abnormalities and repetitive behaviors (which are most sever in boys) in ASD patients.

4.1. Executive functions deficits association with *NRG1* {#s0120}
---------------------------------------------------------

Results of neuropsychological battery of EF measures across three domains (response inhibition, vigilance and working memory) were confirmed previous studies about EF deficit in ASD patients \[[@bb0095],[@bb0150]\]. Associations between schizophrenia related risk allele of *NRG1* and *NRG3* with memory and attention deficits had been previously reported \[[@bb0155],[@bb0160]\]. In addition impacts of type I over expression on working memory abnormalities was reported in transgenic mice \[[@bb0165]\]. Present findings were showed impacts of down regulation of *NRG1* types on working memory and attention deficits which may cause by abnormalities in neuronal plasticity, gelial cell functions and sensorimotor. Type III which is a sensory and motor neuron-derived factor has showed strongest correlation with all three domains.

NRG1 mRNA level increase by particular antipsychotic treatments in schizophrenic patients \[[@bb0170],[@bb0175]\]. Correlation of *NRG1* down regulation with executive functions deficits that were detected in ASD patients may suggest that same antipsychotic treatments might increase *NRG1* mRNA level and improve executive functions such as memory and attention in ASD patients as well.

Neuroimaging assessments in addition to gene expression and genotyping examinations could provide more reliable results about role of neuregulin family and their receptors in ASD. Also evaluation of antipsychotic effects on *NRG1* mRNA level in ASD patients would provide interesting data for therapists.

5. Conclusion {#s0125}
=============

We primarily suggest involvement of *NRG1* main types in etiology of autism spectrum disorders. Correlation of executive functions deficits with down regulation of *NRG1* types have showed important role of *NRG1* in orchestration of number of executive functions including response inhibition, vigilance and working memory in ASD patients.
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[^1]: VRCQ = Visual Response Control Quotient, ARCQ = Auditory Response Control Quotient, VAQ = Visual Attention Quotient, AAQ = Auditory Attention Quotient, SSP = Spatial Span, SWM = Spatial Working Memory,

[^2]: VRCQ = Visual Response Control Quotient, ARCQ = Auditory Response Control Quotient, VAQ = Visual Attention Quotient, AAQ = Auditory Attention Quotient, SSP = Spatial Span, SWM = Spatial Working Memory.

[^3]: VRCQ = Visual Response Control Quotient, ARCQ = Auditory Response Control Quotient, VAQ = Visual Attention Quotient, AAQ = Auditory Attention Quotient, SSP = Spatial Span, SWM = Spatial Working Memory.
